Clinical Research Directory

Inclusion Criteria: * Voluntarily agrees to participate in the clinical study and signs a written informed consent form. * Age between 18 and 75 years, with histologically confirmed recurrent or persistent ovarian clear cell carcinoma. * Has received at least one prior line of platinum-based chemotherapy. * ECOG performance status of 0-2. * Expected survival greater than 12 weeks. * Has measurable disease as defined by RECIST version 1.1: * Each lesion must measure ≥10 mm in its longest diameter by CT, MRI, or clinical examination; * Lesions measured by chest X-ray must be ≥20 mm; * Lymph nodes must have a short axis ≥15 mm when measured by CT or MRI. * At least 4 weeks have elapsed since the last systemic anticancer therapy. * Hematologic, hepatic, renal, thyroid, and cardiac enzyme tests are within normal limits. Exclusion Criteria: * Non-clear cell histologic subtype of ovarian carcinoma. * Prior treatment with immune checkpoint inhibitors, including PD-1, PD-L1, or CTLA-4 inhibitors. * Contraindications to anlotinib, including but not limited to: history of gastrointestinal perforation; surgery within 28 days before combination therapy or unhealed wounds; severe bleeding or recent hemoptysis; or any other condition deemed unsuitable for anlotinib use by the investigator. * Known allergy to irinotecan, anlotinib, or sintilimab. * Brain metastases requiring surgical intervention. * History of other malignancies within the past 5 years. * Active autoimmune disease within the past 2 years. * Vaccination within 1 month prior to study enrollment. * Blood transfusion or platelet transfusion within 4 weeks before first dosing. * Systemic corticosteroid therapy (excluding topical, inhaled, or intranasal corticosteroids) or any other form of immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, thalidomide, or anti-TNF agents) within 7 days prior to first dosing. * Use of systemic antitumor traditional Chinese medicine or immunomodulatory agents (e.g., thymosin, interferon, interleukin) within 2 weeks before first dosing, except for local use to control pleural effusion. * Continuous use of aspirin (\>325 mg/day) or other nonsteroidal anti-inflammatory drugs known to inhibit platelet function for 10 consecutive days within 10 days before first dosing. * Continuous full-dose oral or parenteral anticoagulant or thrombolytic therapy for 10 consecutive days within 10 days before first dosing. * Hereditary bleeding tendency or coagulation disorder; history of hypertension with thrombosis; tumor invasion of major vessels, or radiologic evidence suggesting risk of bleeding, as determined by the investigator or radiologist. * Presence of serious unhealed wounds, ulcers, or fractures. * History of allogeneic organ transplantation (except corneal transplant) or allogeneic hematopoietic stem cell transplantation. * Known history of human immunodeficiency virus (HIV) infection (positive HIV-1/2 antibodies). * Untreated active hepatitis B infection (defined as HBsAg positive with detectable HBV-DNA copies). * Unresolved toxicities from prior therapy (≥Grade 2), except for alopecia, neuropathy, lymphopenia, or skin depigmentation. * Presence of severe or uncontrolled systemic diseases